We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM)
J Clin Oncol
We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenstro¨m macroglobulinemia (WM)
Bortezomib-dexamethasone-rituximab was the most frequently delivered regimen (62%), followed by bortezomib-dexamethasone (18%)
Rituximab is a key component of WM treatment, and has been evaluated in combination with bortezomib [4,5], dexamethasone and bortezomib (BDR) [6, 7]; dexamethasone and cyclophosphamide
As such, we examined the activity of combined bortezomib, dexamethasone and rituximab in patients with the consensus panel diagnosis of WM
Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al
To improve these results, we designed a phase II study that included previously
PURPOSE Rituximab/chemotherapy is a cornerstone of treatment for Waldenstrom¨ ’s macroglobulinemia (WM)
This randomized phase I/II trial studies the side effects and the best dose of temsirolimus when given together with bortezomib, rituximab, and dexamethasone and to see how well they work compared to bortezomib, rituximab, and dexamethasone alone in treating patients with untreated or relapsed Waldenstrom macroglobulinemia or
7509 Background: Waldenstrom macroglobulinemia (WM) is a rare lymphoma for which scant comparative data exist to guide frontline therapy
has demonstrated significant clinical activity of the combination of bortezomib, dexamethasone, and rituximab (BDR) as upfront therapy for WM
Dexamethasone is available as 500microgram and 2mg tablets
Targeting NF-kappaB in Waldenstrom macroglobulinemia
Patients and Methods Patients who had at least one previous therapy were eligible
3 mg/m 2 , and 44% (12/27) received a dose of 1
7509 Background: Waldenstrom macroglobulinemia (WM) is a rare lymphoma for which scant comparative data exist to guide frontline therapy
García-Sanz +11 authors P